R-MVST Cells for Treatment of Viral Infections

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirusBK Virus Infection
Interventions
DRUG

Rapidly generated virus specific T (R-MVST) cells

"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER